Last updated: May 24, 2026
Executive summary: Azelastine hydrochloride is supplied through a mix of API manufacturers and finished-dose product makers. The supply chain is dominated by global generics and ophthalmic/nasal formulation specialists, with API typically sourced from China and India intermediates, then compounded into nasal spray and ophthalmic solutions by regional finished-dose plants. Without specific dosage form and jurisdiction, the supplier set cannot be reduced to a precise “who supplies your market” list.
Which companies supply azelastine hydrochloride API?
Most sourcing decisions start at the API level because manufacturers of finished azelastine products typically buy bulk drug substance under commercial supply agreements or integrated internal capacity.
Common API sourcing pattern (how deals are structured)
- API is typically supplied as azelastine hydrochloride (drug substance) under cGMP for regulated markets (EU/US).
- Finished-dose manufacturers then develop drug product manufacturing processes (nasal spray or ophthalmic solution), which can be tied to local site approvals and DMF/CEP pathways.
API versus drug product: why it changes the supplier list
- API supplier lists are longer and more global.
- Drug product suppliers are fewer and depend on each country’s registration, labels, and local marketing authorization holders.
Who manufactures azelastine hydrochloride nasal spray and who are the key finished-dose suppliers?
Azelastine hydrochloride is marketed most commonly as intranasal therapy (for allergic rhinitis) in the US and EU, with both branded and generic products.
What finished-dose suppliers typically cover
- Metered-dose or spray presentations for allergic rhinitis.
- Single-ingredient azelastine intranasal products.
- Combination products in some markets (for example azelastine plus intranasal corticosteroids), where suppliers usually control both formulation IP and local registration dossiers.
Supplier selection drivers in nasal spray
- Local device and spray pump compatibility
- Preservative and excipient system consistency
- Bioequivalence requirements and stability data for the marketed strength and formulation
Who supplies azelastine hydrochloride ophthalmic solutions (eye drops)?
Azelastine hydrochloride is also supplied as ophthalmic drops for allergic conjunctivitis. Ophthalmic supply chains differ from nasal in sterile manufacturing, fill-finish, and container closure system controls.
Ophthalmic manufacturing constraints that affect suppliers
- Sterile processing capabilities (aseptic fill-finish)
- Compatibility with dropper systems and sterility assurance testing
- Regulatory documentation for preservatives and ocular tolerability
Are there licensing or brand-linked supplier constraints for azelastine?
Brand and originator-linked constraints can affect sourcing indirectly through:
- Market exclusivity windows and supply agreements tied to branded launches
- Post-approval formulations and device-specific registrations
- Patent-protected formulations or delivery systems (where applicable)
What this means for suppliers
Even if multiple API vendors exist, finished-dose availability depends on:
- Whether a finished-dose manufacturer can file and maintain an approved marketing authorization for its exact formulation and device
- Whether manufacturing sites have accepted validation packages for that product line
What generic entry risks affect supply continuity for azelastine hydrochloride?
Generic entry risks affect availability and pricing, even when API supply is adequate.
Risk channels
- Delays or failures in bioequivalence studies for specific presentations
- Regulatory actions impacting manufacturing sites
- Changes in container closure systems requiring bridging studies
- Supplier qualification cycles at distributors and wholesalers
How can you identify the real-world azelastine supplier base for a specific market?
A practical way to map suppliers is through regulatory and procurement artifacts rather than marketing lists:
- FDA/EMA product registrations by dosage form (nasal spray vs ophthalmic)
- Listed manufacturing sites on product labels and regulatory filings
- Tender and distribution disclosures where distributors name manufacturers or relabelers
- DMF/CEP-linked evidence for API origins (where publicly disclosed)
Key takeaways
- Azelastine hydrochloride sourcing typically splits into API suppliers and finished-dose manufacturers, with different qualification and regulatory requirements for nasal versus ophthalmic products.
- The API supplier set is broader and often global, while finished-dose suppliers depend on market registrations, device systems, and sterile manufacturing capability.
- Supplier lists change materially based on dosage form (nasal spray vs ophthalmic solution) and jurisdiction (US vs EU vs other markets).
FAQs
1) Who are the top azelastine hydrochloride API suppliers in China and India?
This depends on which regulatory status (DMF/CEP) and which purity specification you need.
2) Which manufacturers make azelastine hydrochloride nasal spray generics in the US?
US generic availability depends on Orange Book status per strength and formulation, plus device compatibility and bioequivalence approvals.
3) What FDA-approved drug products contain azelastine hydrochloride eye drops?
Ophthalmic product suppliers vary by strength and formulation, and depend on sterile manufacturing and preservatives used.
4) Can a finished-dose manufacturer buy azelastine API from any vendor?
No. Vendors must meet cGMP and supply-quality requirements, and finished-dose manufacturers must qualify the incoming API and validate the drug product manufacturing process.
5) What drives price volatility for azelastine hydrochloride products?
Regulatory approvals, manufacturing site disruptions, API supply constraints, and generic competition tied to specific presentations drive most volatility.
References (APA)
- [No cited sources provided in the prompt.]
